



# Diseases Treated With Hyperbaric Oxygen Therapy; a Literature Review

Ali Shahriari<sup>1</sup> ; Maryam Khooshideh <sup>2</sup>, Matineh Heidari<sup>3</sup>

<sup>1</sup> Department of Anesthesiology, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>2</sup> Department of Obstetrics and Gynecology, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup> Tehran University of Medical Sciences, Tehran, Iran

## ABSTRACT

Hyperbaric oxygen therapy (HBO) is defined as the inhalation of 100% oxygen inside a hyperbaric chamber that is pressurized to greater than 1 atmosphere (Atm). Typical HBO regimens use 1.5 to 2.5 Atm pressure for durations of 30 to 90 minutes, repeated multiple times. The time between and the total number of repeat sessions varies widely. The effectiveness of hyperbaric oxygen therapy for treatment of some diseases such as intravascular emboli, decompression sickness, anaerobic infections, CO poisoning was confirmed. For some diseases, such as traumatic brain injuries, the effectiveness of hyperbaric oxygen therapy as described by investigators is controversial. Chinese authors have reported many articles regarding treatment of neonatal hypoxia with hyperbaric oxygen therapy, but in other points of the world, this depth of experience does not exist. Recently, some other diseases, such as purpura fulminans, and pancreatitis, have been treated by hyperbaric oxygen therapy. In conclusion, if equipment for hyperbaric oxygen therapy is available, many patients will benefit by this method of treatment.

## KEY WORDS

Hyperbaric oxygen therapy, diseases, studies.

©2013, Med Hypothesis Discov Innov Interdisciplinary

This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

---

## Correspondence to:

Maryam Khooshideh, Email:Khooshide@yahoo.com

---

## INTRODUCTION

Hyperbaric oxygen therapy (HBO) is defined as the inhalation of 100% oxygen inside a hyperbaric chamber that is pressurized to greater than 1 atmosphere (Atm). Typical HBO regimens use 1.5 to 2.5atm pressure for durations of 30 to 90 minutes, repeated multiple times. The elevated pressure of oxygen in these chambers leads

to patients showing elevated arterial PO<sub>2</sub> and thus improvement of ischemic conditions. The time between and the total number of repeat sessions varies widely in studies (1).

Hemoglobin and nitric oxide independently fulfill diverse and complex physiological roles in the body; together they subtly modulate microvascular perfusion in



response to second-by-second changes in local metabolic demand, contributing to hypoxic vasodilation (2). By increasing tissue PO<sub>2</sub> hyperbaric oxygen therapy reverses this phenomenon and induces vasoconstriction by inactivating nitric oxide as a result of increased production of superoxide (3,4).

### **Venous or Arterial Gas embolism**

Gas embolism is well described in the medical literature and nearly always reported as an iatrogenic complication, related to surgery or following trauma. It has been associated with positive pressure mechanical ventilation, the insertion (and removal) of central lines and empty IV infusion set-ups (5,6). It is a known complication of cardiac surgery with an incidence of approximately 0.1%, whether following bypass pump failure or by the introduction of gas in the surgical field. Other described sources of gas embolism include ingestion or colonic irrigation with hydrogen peroxide, and inhalation of pressurized helium. In the gynecologic literature, gas embolism is extensively described as occurring when air is introduced into venous plexuses of the uterus; for example, during douching, illegal abortion, urogenital sex during pregnancy, labor and delivery, laparoscopy, or hysteroscopy with CO<sub>2</sub> laser (7). Lastly, it has been increasingly recognized as a complication of serious chest trauma, presumably through the creation of aero-vascular fistulas (8).

The signs and symptoms of gas emboli depend on the amount, nature, and end-position of the introduced gas. Diagnosis is often presumptive, with suggestive signs and symptoms accompanied by a portal of gas entry. Small emboli in skeletal muscle or visceral vessels are usually well tolerated (7). Cerebral, coronary, and pulmonary emboli, however, can result in serious morbidity and mortality. Cerebral embolisms may cause headaches, visual disturbances, altered mentation, weakness, sensory defects, seizures, respiratory arrest, or death. Coronary emboli can cause dysrhythmias, hypotension, and myocardial infarction, whereas pulmonary gas emboli may lead to hypoxia, hypercapnia, and acute respiratory distress syndrome (ARDS) (3,9). Air in the microcirculation can lead to disseminated intravascular coagulation (DIC), tissue ischemia, and gastrointestinal mucosal damage. Physical examination may reveal a “mill wheel” murmur on cardiac auscultation, skin marbling, blanching of the nail beds, pallor of the mucous

membranes, or more rarely, air bubbles in the retinal arteries. Echocardiography can be a very useful adjunct in diagnosing intracardiac gas emboli. A head CT scan may reveal subtle changes in cerebral arterial gas embolism, but is not routinely reliable, especially in early diagnosis (10,11). In general, the universally lethal volume of embolized gas in an adult is not known, but is estimated at 200–300 mL of introduced air.

Administration of 100% oxygen, crystalloids infusion, and supportive care are the mainstays of gas embolism therapy. In an effort to decrease cerebral emboli, Trendelenburg positioning is often recommended, as it is thought to decrease the volume of gas “rising” to the cerebral circulation (4,13). More recently, others have recommended flat supine positioning, stressing that Trendelenburg positioning is not only unhelpful in preventing the propulsion of bubbles into cerebral arteries, but may actually aggravate cerebral edema (7,13,14). In aiming to reduce cerebral edema and damage, corticosteroids were previously, but no longer routinely recommended, though various studies have found intravenous lidocaine therapy to be helpful (7,15). Closed chest cardiac massage, in the setting of cardiopulmonary arrest, may also help mechanically with the breakup and dissolution of embolic gas bubbles.

Symptomatic cerebral or coronary air emboli, as suggested in this case, necessitate serious consideration of hyperbaric oxygen therapy (13,16,17). The rationale is based on principles of gas physiology, and this is clinically reinforced. Room air emboli are composed primarily of oxygen and nitrogen. At atmospheric pressure, oxygen readily reabsorbs into solution, but nitrogen remains insoluble and in potentially embolic bubble form. Both high-flow oxygen and hyperbaric oxygen therapy are standard treatments that decrease the size and absorption time of excess bloodstream nitrogen.

“Hyperoxygenation” works not only to oxygenate end organs, but also facilitates the absorption of residual nitrogen. Room air is composed of 80% nitrogen and 20% oxygen, but as the oxygen tension is increased in the blood, the “O<sub>2</sub> window” for nitrogen removal is widened. Hyperoxygenation, increasing blood oxygen tension, facilitates nitrogen removal from embolic bubbles by steepening nitrogen bubbles’ downstream gradient into hyperoxygenated (i.e., nitrogen-poor) blood. Clinically, a 4-mm diameter nitrogen bubble disappears in 560 min



on room air, or 56 min on 100% oxygen. Additionally, hyperbaric pressure physically compresses embolic bubbles. Any gas volume varies inversely with ambient pressure (i.e., Boyle's law), thus, at three atmospheres of pressure, a bubble's volume would be but one-third its volume at sea level

Although no formal trials support the use of hyperbaric oxygen in air embolism, well-established pathophysiology and extensive successful clinical experience justify its use as the primary treatment (18). Predictably, the efficacy of hyperbaric therapy is inversely proportional to time elapsed since the embolic event. Benefit is reported when therapy begins several hours after the onset of air embolism (19).

### **Neonatal hypoxia**

The Chinese medical literature may be a rich source of evidence to inform clinical practice and other systematic reviews have also concluded that treatment with hyperbaric oxygen possibly reduces mortality and neurological sequels in term neonates with hypoxic-ischemic encephalopathy (20).

For example, in their study Liu et al. concluded that early HBO treatment with 2 atmospheres resulted in a protective effect against hypoxic-ischemic brain damage-induced long-term brain morphological and histological deficits and spatial learning and memory disability (21).

Additionally, Calvert et al. (22) reported that hyperbaric oxygen (HBO) could be a treatment for neonatal hypoxia-ischemia in a neonatal rat model and could prevent brain injury. In that study, HBO was administered in a chamber for 1 hour at 3 atm (atmospheres), 1 hour after hypoxia exposure. Results suggested that HBO, as a single therapy, is able to attenuate hypoxia-ischemia brain insult and offer neuroprotectivity. The HBO reduced neuronal injury with much less atrophy and apoptosis of immature neurons, resulting in further improvement of sensorimotor function of neonatal brain.

### **Cerebral ischemia**

Clinical and experimental evidence suggests that a localized decrease in oxygen brain tissue availability contributes to the neurological deficit in patients with cerebrovascular disease (CVD) who also present with frontal leukoaraiosis (LA) (periventricular hypodensity on CT scan) and lacunar infarcts. In their study, Vila et al.

(23) compared selected patients with symptomatic CVD, LA and lacunar infarcts who received daily exposures to hyperbaric oxygen of 45 min for 10 days with a control of similar patients treated with hyperbaric air. They concluded that there was a statistically significant improvement in all scales for the HBO2 group compared with the placebo group. Neurological improvement persisted in the majority of patients in the HBO group for up to 6 months. Repetition of the HBO2 protocol in 9 patients in whom symptoms recurred after 6 months resulted in improvement of symptoms.

The effectiveness of both normobaric hyperoxia and HBO in experimental transient focal ischemia has been shown by the majority of experimental studies (24–26). In the majority of clinical strokes, however, the occluded vessel fails to reopen rapidly (26)—a setting that is only appropriately reflected in permanent ischemia models.

Veltkamp et al. (27) reported that HBO significantly reduced histological infarct size at 24 h. In their study, 48 Wistar rats underwent filament occlusion of the middle cerebral artery (MCAO). Forty minutes after MCAO, the rats were placed in an HBO chamber and breathed either 100% O<sub>2</sub> at 3.0 Atm absolute or at 1.0 Atm for 1 h. Diffusion, perfusion and T<sub>2</sub>-weighted MR-images were obtained after 15 min and 3, 6 and 24 h of reperfusion. The researchers found that high-dose HBO therapy has an immediate protective effect on the brain that is superior to normobaric oxygen.

Another study by Veltkamp et al. (28) provides several new findings. First, both normobaric hyperoxia and HBO therapy reduced infarct volume in a cortical permanent ischemia model. Remarkably, HBO provided significantly larger protection than normobaric hyperoxia in animal models when started within 120 min after occlusion of the middle cerebral artery. Repeated HBO treatment courses on subsequent days had no additional effect. In contrast, in filament-induced permanent subcortical and cortical ischemia, normobaric hyperoxia and HBO were ineffective, whereas HBO reduced infarct size compared to normobaric hyperoxia in transient filament occlusion of the middle cerebral artery.

### **Traumatic brain injury**

Use of hyperbaric oxygen therapy (HBO) to treat traumatic brain injury is controversial, with implications for clinicians, patients, and health care systems. HBO is



used to treat patients with traumatic brain injury at some hyperbaric centers, but it is not widely accepted as effective for this indication. The potential mechanism of action of HBO in treating traumatic brain injury has not been fully elucidated. Its use in traumatic brain injury is based on the theory that damaged cells are in the ischemic penumbra (the border between healthy and damaged brain tissue), which may have the potential to be recovered (29,30). Improving oxygen availability to these cells may stimulate them to function normally, reactivating them metabolically or electrically, ultimately resulting in angiogenesis and other signs of healing (30). However, the potential for recovery may be diminished as the time postinjury increases (30). This theory is controversial, even though there is evidence that secondary ischemia and oxygen deficiency are important mechanisms of cell death in traumatic brain injury (31).

Studies in humans showing improvements in blood flow to injured areas, as documented by serial single proton emission computed tomography scans, and changes in cerebral metabolism in patients with traumatic brain injury after HBO help to support this theory (30–33).

The evidence is insufficient, however, to prove the effectiveness or ineffectiveness of HBO for traumatic brain injury, and other high-quality studies are needed (34).

### **Cardiac ischemia**

Normobaric therapy has been in use for many years in the treatment of ischemic heart disease (35). When oxygen is breathed in concentrations higher than those found in the atmospheric air, it is considered to be a drug. A limited amount of oxygen is dissolved in blood at normal atmospheric pressure, but under hyperbaric conditions it is possible to dissolve sufficient oxygen, for example 6%, in plasma to meet the usual requirements of the body. The oxygen physically dissolved in solution will be utilized more readily than that bound to hemoglobin, and this effect may normalize or increase oxygen tension in ischemic tissue (35).

The role of HBO in patients with acute myocardial infarction is debatable, ranging from no beneficial effect (36,37) to a favorable effect (38,39). The only controlled trial was completed by Thurston et al. (38) in the prethrombolytic area and revealed a trend, but not a statistically significant decrease, in mortality rates

especially in high-risk patients. An animal study conducted by Thomas et al. (39) proved the hypothesis that a combination of thrombolytic therapy and HBO would be more effective in reducing the size of the myocardial infarction than either of these modalities alone. Therefore, a randomized pilot trial conducted by Shandling et al. (40) demonstrated that adjunctive treatment with HBO appears to be feasible and safe for patients in the acute phase of myocardial infarction. Finally, the Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction study (41) demonstrated that treatment with HBO in combination with thrombolysis might result in an attenuated creatine phosphokinase rise, more rapid resolution of pain, and improved ejection fraction (42).

The effect of hyperbaric oxygen therapy on the bout of treatment for soft tissue infections

Tissue oxygen tensions are affected mainly by the concentration of inspired oxygen, cardiac output, local blood flow, cellular metabolism and substrate availability (43). Partial pressures of oxygen (PO<sub>2</sub>) are normally different in various body compartments. When the PO<sub>2</sub> in normal and infected tissues were measured with an oxygen microelectrode, dramatic decreases were found at the site of infection (44). A critical step in the killing of bacteria by polymorphonuclear neutrophils (PMN) is the production of H<sub>2</sub>O<sub>2</sub>; however, the ability of the PMN to produce H<sub>2</sub>O<sub>2</sub> is decreased under anaerobic conditions (45). Hohn showed that the killing efficiency of human neutrophils for *Staphylococcus Aureus* was impaired by PO<sub>2</sub> levels below 15 mmHg and severely decreased at levels from 5 to 0 mmHg (46). The decrease in tissue PO<sub>2</sub> from the normal 60 mmHg to less than 10 mmHg corresponds with the influx of leukocytes (44). The aim of HBO is to increase transported oxygen in the blood by increasing the physiologically dissolved oxygen. Furthermore, increased local PO<sub>2</sub> is sufficient to influence bacterial killing by neutrophils and HBO has been shown to increase the killing ability of neutrophils (47–49).

Studies have demonstrated that HBO therapy has bacteriostatic and bactericidal activity (50). Hyperoxia increases free-radical production and the increase of super oxide induced by HBO is toxic to both anaerobic and aerobic bacteria (43). Mader demonstrated that HBO alone was as effective as an antibiotic in the treatment of



experimental osteomyelitis due to *Staphylococcus Aureus* in rabbits (51).

Additionally, HBO improves wound oxygenation so that host factors are able to control infection and function to heal the wound. Collagen synthesis in wounds is accelerated by exposure to moderate hyperoxia. Hunt showed the oxygen dependency of collagen production by fibroblasts (52). In another experimental study (53), HBO therapy has been shown to reduce skeletal muscle edema and necrosis in rat hind limb tourniquet ischemia, and in dog hind limb compartment syndrome models. In several mechanisms, HBO can enhance the effect of antibiotic therapy. In conclusion, HBO therapy combined with antibiotic therapy for soft tissue infections is recommended.

There was also a clear clinical correlation between O<sub>2</sub> availability via a face mask and the development of wound infection. A study by Grief et al. (54) provided additional clinical evidence that enhancing wound O<sub>2</sub> levels through the administration of supplemental O<sub>2</sub> can improve the host's immune responses. In their study of 500 patients undergoing abdominal surgery, all of whom received prophylactic antibiotics, administration of O<sub>2</sub> at an 80% FiO<sub>2</sub> during surgery and for 2 hours postoperatively resulted in a 5.2% wound infection rate versus an 11.2% infection rate in patients given O<sub>2</sub> at a 30% FiO<sub>2</sub> (54).

### **Treatment of acute carbon monoxide poisoning**

The guideline 'Treatment of acute carbon monoxide poisoning' from doctors in clinics with a tank for hyperbaric ventilation shows that carbon monoxide (CO) poisoning is a potentially life-threatening emergency. Its prognosis is linked to prompt recognition and treatment. CO is toxic because it binds to hemoglobin (Hb), thus impairing oxygen transport and causing tissue hypoxia. The most important symptoms are headache and altered consciousness, ranging from somnolence to coma. The diagnosis is based on a history of CO exposure combined with an elevated carboxyhemoglobin (HbCO) level in the blood. On the basis of the available literature, it is recommended that patients with an HbCO level > or = 10% should always be treated. In patients requiring artificial ventilation, 100% oxygen for 8 hours is recommended. In pregnant women and in patients who

are or have been comatose, hyperbaric oxygen can be considered. In all other symptomatic patients, use of a non-rebreathing mask with 100% oxygen for 8 hours is recommended (55).

Recently, a large prospective study showed that hyperbaric oxygen improves the results of neuropsychological testing in all CO-poisoned patients, regardless of their consciousness level (56). In CO-poisoned rats without loss of consciousness hyperbaric oxygen therapy was superior to normobaric oxygen in improving survival time, survival rate and reducing neurological morbidity (57,58). These acute effects of hyperbaric oxygen could be the result of reducing brain edema (57–58).

### **Burns**

Hyperbaric oxygen therapy (HBO) can be used as an intervention for burns therapy. It was first suggested for the treatment of thermal burns more than 40 years ago when Wada et al. (59) serendipitously observed more rapid healing of second-degree burns in a group of coal miners who were being treated with HBO for carbon monoxide poisoning. In 1969, Gruber et al. (60) demonstrated that the area sub-adjacent to a full-thickness injury was hypoxic and could be raised to normal or supra-normal levels through the administration of oxygen under pressure. This was followed by a series of animal experiments that demonstrated a significant reduction of edema, improved microcirculation, reduced inflammatory responses, faster epithelialization, and improved wound healing with HBO (61,62).

The modest increase in tissue oxygen tension enables a raft of immune and healing functions in the hypoxic tissue. For example, the process of phagocytosis involves consumption of oxygen in an 'oxidative burst' and although such processes are possible at remarkably low tissue oxygen tensions, improving oxygenation to within or above the physiologic range dramatically improves the efficiency of such activity. Allen et al. (63) has shown that oxygen tensions between 40 and 80 mmHg are required to maintain activity at 50% of maximum in the NADPH-linked oxygenase responsible for this respiratory burst. For it to work at 90% of maximum, oxygen tension of 400 mmHg may be required (63).



In summary, while there is insufficient evidence to recommend routine HBO in the care of thermal burns, there appears to be a case for appropriate clinical investigation of this interesting treatment modality (64).

### **Pain treatment**

Kiralp et al.'s study aimed to assess the effectiveness of hyperbaric oxygen (HBO) therapy for treating patients with complex regional pain syndrome. In the group that received 15 sessions of hyperbaric oxygen therapy there was a significant decrease in pain and edema and a significant increase in the range of motion. They concluded that HBO is an effective and well-tolerated method for decreasing pain and edema and increasing the range of motion in patients with complex regional pain syndrome (65).

A review by Yidiz et al. (66) concluded that HBO may be beneficial if appropriate patients are selected for treatment of fibromyalgia syndrome (67), complex regional pain syndrome, myofascial pain syndrome, migraine, and cluster headaches (66).

### **Other diseases treated with HBO**

There are a wide range of conditions where hyperbaric oxygen therapy is used in addition to traditional methods for treatment of other diseases. These include acute intoxications by psychotropic drugs (68), prevention of leakage from colonic anastomoses (69), treatment of infected free bone transplants (70), purpura fulminans (71), treatment for malabsorption in radiation-damaged short bowel (72), and in the treatment of nephrotic syndrome (73). In addition, it has been reported in the treatment of radiation injuries in gynecological cancers (74), for improving cardiac neural regulation in patients with diabetic autonomic dysfunction (75), for hepatic artery thrombosis following liver transplantation (76); as well as for necrotizing fasciitis (77,78), bacterial endocarditis (79), after microsurgical repair of transected peripheral nerves (80), and for managing pyoderma gangrenosum (81). More specific conditions include ischemic scleroderma wounds (82), radiation-induced proctopathy (83), bacterial brain abscesses (84), idiopathic sudden sensorineural hearing loss and tinnitus (85), cirrhosis (86), malignant otitis externa (87), lymphedema after breast cancer treatment (88), radiation-induced non-healing wounds (89), and Fournier gangrene (90) among other diseases.

### **CONCLUSION**

This review has shown that if equipment for hyperbaric oxygen therapy is available, there are many patients who would benefit from treatment by this method.

### **DISCLOSURE**

Conflicts of Interest: None declared.

### **REFERENCES**

1. Mathieu D, Neviere R, Pellerin P, Patenotre P, Wattel F. Pedicle musculocutaneous flaptransplantation: Prediction of final outcome by transcutaneous oxygen measurements in hyperbaric oxygen. *Plast Reconstr Surg*. 1993 Feb;91(2):329-34. PMID: 8430149
2. Allen BW, Piantadosi CA. How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm. *Am J Physiol Heart Circ Physiol*. 2006 Oct;291(4):H1507-12. PMID: 16751292
3. McMahon TJ, Moon RE, Lusching BP, Carraway MS, Stone AE, Stolp BW, Gow AJ, Pawloski JR, Watke P, Singel DJ, Piantadosi CA, Stamler JS. Nitric oxide in the human respiratory cycle. *Nat Med*. 2002 Jul;8(7):711-7. PMID: 12042776
4. Demchenko IT, Boso AE, Natoli MG, et al. Nitric acid is involved in the mechanism of the brain's vascular responses to oxygen. *Circ Res* 2002;91;1031.
5. Inamasu J, Nakamura Y, Saito R, Ichikizaki K, Shiei K. Cerebral air embolism after central venous catheterization. *Am J Emerg Med*. 2001 Oct;19(6):520-1. PMID: 11593474
6. Halliday P, Anderson DN, Davidson AI, Page JG. Management of cerebral air embolism secondary to a disconnected central venous catheter. *Br J Surg*. 1994 Jan;81(1):71. PMID: 8313127
7. Muth CM, Shank ES. Gas embolism. *N Engl J Med*. 2000 Feb 17;342(7):476-82. PMID: 10675429
8. Ho AM, Ling E. Systemic air embolism after lung trauma. *Anesthesiology*. 1999 Feb;90(2):564-75. PMID: 9952165
9. Dutka AJ. A review of the pathophysiology and potential application of experimental therapies for cerebral ischemia to the treatment of cerebral arterial gas embolism. *Undersea Biomed Res*. 1985 Dec;12(4):403-21. PMID: 4082344
10. Voorhies RM, Fraser RA. Cerebral air embolism occurring at angiography and diagnosed by computerized tomography. *J Neurosurg*. 1984 Jan;60(1):177-8. PMID: 6689713
11. Muras I, Bonsignore R, Cesaro L, Frascadore L, Bernini FP. Post-traumatic cerebral air embolism. Case report. *J Neuroradiol*. 1994 Dec;21(4):267-9. PMID: 7884489
12. Heckmann JG, Lang CJ, Kindler K, Huk W, Erbguth FJ, Neundörfer B. Neurologic manifestations of cerebral air embolism as a complication of central venous catheterization. *Crit Care Med*. 2000 May;28(5):1621-5. PMID: 10834723



13. Thalmann ED. Principles of U.S. navy recompression treatments for decompression sickness. In: Diving Accident Management, 41st Undersea and Hyperbaric Medical Society Workshop. Undersea and Hyperbaric Medical Society publication 78 (DIVACC); 1990. p. 194-221.
14. Moon RE, de Lisle Dear G, Stolp BW. Treatment of decompression illness and iatrogenic gas embolism. *Respir Care Clin N Am*. 1999 Mar;5(1):93-135. PMID: 10205814
15. Kizer KW. Corticosteroids in treatment of serious decompression sickness. *Ann Emerg Med*. 1981 Sep;10(9):485-8. PMID: 7270998
16. Ziser A, Adir Y, Lavon H, Shupak A. Hyperbaric oxygen therapy for massive arterial air embolism during cardiac operations. *J Thorac Cardiovasc Surg*. 1999 Apr;117(4):818-21. PMID: 10096979
17. Peirce EC 2nd. Specific therapy for arterial air embolism. *Ann Thorac Surg*. 1980 Apr;29(4):300-3. PMID: 6965853
18. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. *N Engl J Med*. 1996 Jun 20;334(25):1642-8. PMID: 8628361
19. Doostan DK, Steffenson SL, Snoey ER. Cerebral and coronary air embolism: an intradepartmental suicide attempt. *J Emerg Med*. 2003 Jul;25(1):29-34. PMID: 12865105
20. Liu Z, Xiong T, Meads C. Clinical effectiveness of treatment with hyperbaric oxygen for neonatal hypoxic-ischaemic encephalopathy: systematic review of Chinese literature. *BMJ*. 2006 Aug 19;333(7564):374. PMID: 16690641
21. Liu MN, Zhuang SQ, Zhang HY, Qin ZY, Li XY. Long-term effects of early hyperbaric oxygen therapy on neonatal rats with hypoxic-ischemic brain damage. *Zhongguo Dang Dai Er Ke Za Zhi*. 2006 Jun;8(3):216-20. PMID: 16787595
22. Calvert JW, Yin W, Patel M, Badr A, Mychaskiw G, Parent AD, Zhang JH. Hyperbaric oxygenation prevented brain injury induced by hypoxia-ischemia in a neonatal rat model. *Brain Res*. 2002 Sep 27;951(1):1-8. PMID: 12231450
23. Vila JF, Balcarce PE, Abiusi GR, Dominguez RO, Pisarello JB. Improvement in motor and cognitive impairment after hyperbaric oxygen therapy in a selected group of patients with cerebrovascular disease: a prospective single-blind controlled trial. *Undersea Hyperb Med*. 2005 Sep-Oct;32(5):341-9. PMID: 16457083
24. Helms AK, Whelan HT, Torbey MT. Hyperbaric oxygen therapy of cerebral ischemia. *Cerebrovasc Dis*. 2005;20(6):417-26. PMID: 16230845
25. Günther A, Küppers-Tiedt L, Schneider PM, Kunert I, Berrouschot J, Schneider D, Rossner S. Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischemia. *Eur J Neurosci*. 2005 Jun;21(11):3189-94. PMID: 15978027
26. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke*. 2005 Jan;36(1):66-73. PMID: 15569863
27. Veltkamp R, Siebing DA, Heiland S, Schoenfeldt-Varas P, Veltkamp C, Schwaninger M, Schwab S. Hyperbaric oxygen induces rapid protection against focal cerebral ischemia. *Brain Res*. 2005 Mar 10;1037(1-2):134-8. PMID: 15777761
28. Veltkamp R, Sun L, Herrmann O, Wolferts G, Haggmann S, Siebing DA, Marti HH, Veltkamp C, Schwaninger M. Oxygen therapy in permanent brain ischemia: Potential and limitations. *Brain Res*. 2006 Aug 30;1107(1):185-91. PMID: 16828721
29. Neubauer RA. Idling neurons. *Lancet*. 1990 May 19;335(8699):1217. PMID: 1971055
30. Jain KK, Camporesi EM (editors). Textbook of hyperbaric medicine. 3rd ed. Kirkland (WA): Hogrefe and Huber; 1999.
31. Robertson CS, Valadka AB, Hannay HJ, Contant CF, Gopinath SP, Cormio M, Uzura M, Grossman RG. Prevention of secondary ischemic insults after severe head injury. *Crit Care Med*. 1999 Oct;27(10):2086-95. PMID: 10548187
32. Barrett K, Harch P, Masel B, Patterson J, Korson K, Mader J. Cognitive and cerebral blood flow improvements in chronic stable traumatic brain injury induced by 1.5 ATA hyperbaric oxygen. *Undersea Hyperbaric Med*. 1998;25(9).
33. Nighoghossian N, Trouillas P. Hyperbaric oxygen in the treatment of acute ischemic stroke: an unsettled issue. *J Neurol Sci*. 1997 Sep 1;150(1):27-31. PMID: 9260854
34. McDonagh M, Helfand M, Carson S, Russman BS. Hyperbaric oxygen therapy for traumatic brain injury: a systematic review of the evidence. *Arch Phys Med Rehabil*. 2004 Jul;85(7):1198-204. PMID: 15241774
35. Jain KK. Hyperbaric oxygen therapy in cardiovascular diseases. In: Jain KK, editor. Textbook of Hyperbaric Medicine. Seattle: Hogrefe and Huber; 1990. p. 283-307.
36. Cameron AJ, Hutton I, Kenmure AC, Murdoch WR. Hemodynamic and metabolic effects of hyperbaric oxygen in myocardial infarction. *Lancet*. 1966 Oct 15;2(7468):833-7. PMID 4162172
37. Ashfield R, Gavey CJ. Severe acute myocardial infarction treated with hyperbaric oxygen: report on forty patients. *Postgrad Med J*. 1969 Oct;45(528):648-54. PMID: 5358380
38. Thurston JB, Greenwood TW. Results of a controlled trial of hyperbaric oxygen in acute myocardial infarction. *Q J Med*. 1973;168:752-70.
39. Thomas MP, Brown LA, Sponseller DR, Williamson SE, Diaz JA, Guyton DP. Myocardial infarction size reduction by synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator. *Am Heart J*. 1990 Oct;120(4):791-800. PMID: 2121010
40. Shandling AH, Ellestad MH, Hart GB, Crump R, Marlow D, Van Natta B, Messenger JC, Strauss M, Stavitsky Y. Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction: the "HOT MI" pilot study. *Am Heart J*. 1997 Sep;134(3):544-50. PMID: 9327714
41. Stavitsky Y, Shandling AH, Ellestad MH, Hart GB, Van Natta B, Messenger JC, Strauss M, Dekleva MN, Alexander JM, Mattice M, Clarke D. Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction: the "HOT MI" Randomized Multicenter Study. *Cardiology*. 1998 Oct;90(2):131-6. PMID: 9778551
42. Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis



on left ventricular function in patients with acute myocardial infarction. *Am Heart J.* 2004 Oct;148(4):E14. PMID: 15459609

43. Park MK, Myers RA, Marzella L. Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. *Clin Infect Dis.* 1992 Mar;14(3):720-40. PMID: 1562664

44. Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic. A comparison of the effects of inspired oxygen concentration and antibiotic administration on in vivo bacterial clearance. *Arch Surg.* 1986 Feb;121(2):191-5. PMID: 3511888

45. Hays RC, Mandell GL. PO<sub>2</sub>, pH, and redox potential of experimental abscesses. *Proc Soc Exp Biol Med.* 1974 Oct;147(1):29-30. PMID: 4612550

46. Hohn DC, MacKay RD, Halliday B, Hunt TK. Effect of O<sub>2</sub> tension on microbicidal function of leukocytes in wounds and in vitro. *Surg Forum.* 1976;27(62):18-20. PMID: 1019847

47. Kindwall EP. Uses of hyperbaric oxygen therapy in the 1990s. *Cleve Clin J Med.* 1992 Sep-Oct;59(5):517-28. PMID: 1468134

48. Sugihara A, Watanabe H, Oohashi M, Kato N, Murakami H, Tsukazaki S, Fujikawa K. The effect of hyperbaric oxygen therapy on the bout of treatment for soft tissue infections. *J Infect.* 2004 May;48(4):330-3. PMID: 15066334

49. Park MK. Effects of hyperbaric oxygen in infectious diseases: basic mechanisms. In: Kindwall EP. (editor). *Flagstaff, AZ: Best Publishing; 1994/ p. 141-172.*

50. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. *N Engl J Med.* 1996 Jun 20;334(25):1642-8. PMID: 8628361

51. Mader JT, Guckian JC, Glass DL, Reinartz JA. Therapy with hyperbaric oxygen for experimental osteomyelitis due to *Staphylococcus aureus* in rabbits. *J Infect Dis.* 1978 Sep;138(3):312-8. PMID: 701849

52. Hunt TK, Pai MP. The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. *Surg Gynecol Obstet.* 1972 Oct;135(4):561-7. PMID: 5077722

53. Zamboni WA, Roth AC, Russell RC, Graham B, Suchy H, Kucan JO. Morphologic analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen. *Plast Reconstr Surg.* 1993 May;91(6):1110-23. PMID: 8479978

54. Greif R, Akça O, Horn EP, Kurz A, Sessler DI; Outcomes Research Group. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. *N Engl J Med.* 2000 Jan 20;342(3):161-7. PMID: 10639541

55. de Pont AC. The guideline 'Treatment of acute carbon-monoxide poisoning' from doctors in clinics with a tank for hyperbaric ventilation. *Ned Tijdschr Geneeskd.* 2006 Mar 25;150(12):665-9. PMID: 16613249

56. Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, Orme JF Jr, Thomas FO, Morris AH. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med.* 2002 Oct 3;347(14):1057-67. PMID: 12362006

57. Jiang J, Tyssebotn I. Normobaric and hyperbaric oxygen treatment of acute carbon monoxide poisoning in rats. *Undersea Hyperb Med.* 1997 Jun;24(2):107-16. PMID: 9171469

58. Jiang J, Tyssebotn I. Cerebrospinal fluid pressure changes after acute carbon monoxide poisoning and therapeutic effects of normobaric and hyperbaric oxygen in conscious rats. *Undersea Hyperb Med.* 1997 Winter;24(4):245-54. PMID: 9444057

59. Wada J, Ikeda T, Kamata K, Ebuoka M. Oxygen hyperbaric treatment for carbon monoxide poisoning and severe burn in coal mine (hokutanyubari) gas explosion, Igakunoayami. 1965;5:53.

60. Gruber RP, Brinkley FB, Amato JJ, Mendelson JA. Hyperbaric oxygen and pedicle flaps, skin grafts, and burns. *Plast Reconstr Surg.* 1970 Jan;45(1):24-30. PMID: 4902839

61. Korn HN, Wheeler ES, Miller TA. Effect of hyperbaric oxygen on second degree burn wound healing. *Arch Surg.* 1977 Jun;112(6):732-7. PMID: 558743

62. Nylander G, Nordström H, Eriksson E. Effects of hyperbaric oxygen on oedema formation after a scald burn. *Burns Incl Therm Inj.* 1984 Feb;10(3):193-6. PMID: 6722608

63. Allen DB, Maguire JJ, Mahdavian M, Wicke C, Marocci L, Scheuenstuhl H, Chang M, Le AX, Hopf HW, Hunt TK. Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. *Arch Surg.* 1997 Sep;132(9):991-6. PMID: 9301612

64. Wasiak J, Bennett M, Cleland HJ. Cleland. Hyperbaric oxygen as adjuvant therapy in the management of burns: Can evidence guide clinical practice? *Burns.* 2006 Aug;32(5):650-2. PMID: 16777333

65. Kiralp MZ, Yildiz S, Vural D, Keskin I, Ay H, Dursun H. Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome. *J Int Med Res.* 2004 May-Jun;32(3):258-62. PMID: 15174218

66. Yildiz S, Uzun G, Kiralp MZ. Hyperbaric oxygen therapy in chronic pain management. *Curr Pain Headache Rep.* 2006 Apr;10(2):95-100. PMID: 16539861

67. Yildiz S, Kiralp MZ, Akin A, Keskin I, Ay H, Dursun H, Cimsit M. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. *J Int Med Res.* 2004 May-Jun;32(3):263-7. PMID: 15174219

68. Epifanova NM, Romasenko MV, Kukshina AA, Iakovlev Alu, Zubareva OV. Psychoneurological disorders in acute intoxications by psychotropic drugs and their correction using hyperbaric oxygenation. *Anesteziol Reanimatol.* 2006 Mar-Apr;(2):54-7. PMID: 16758946

69. Yagci G, Ozturk E, Ozgurtas T, Gorgulu S, Kutlu OC, Topal T, Cetiner S, Tufan T. Preoperative and postoperative administration of hyperbaric oxygen improves biochemical and mechanical parameters on ischemic and normal colonic anastomoses. *J Invest Surg.* 2006 Jul-Aug;19(4):237-44. PMID: 16835138

70. Lentrodt S, Lentrodt J. Effects of hyperbaric oxygen therapy (HBO) during treatment of infected free bone transplants. A Case report. *Mund Kiefer Gesichtschir.* 2006 Jul;10(4):263-8. PMID: 16786363

71. Tilelli JA, Farrell MM. Hyperbaric oxygen therapy for purpura fulminans-comment. *Pediatr Emerg Care.* 2006 May;22(5):394. PMID: 16714977

72. Huddy JE, Patel P, Johnson MW, Hamilton-Farrell MR, Ede RJ, Sanderson JD. Hyperbaric oxygen as a treatment for malabsorption in a radiation-damaged short bowel. *Eur J Gastroenterol Hepatol.* 2006 Jun;18(6):685-8. PMID: 16702860





73. Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, Eyiletin T, Yenicesu M, Acikel C, Oter S, Yaman H, Aktug H, Oguz Y, Vural A, Ikizler TA. Hyperbaric Oxygen Treatment Augments the Efficacy of a Losartan Regime in an Experimental Nephrotic Syndrome Model. *Nephron Exp Nephrol*. 2006;104(1):e15-22. PMID: 16699289
74. Fink D, Chetty N, Lehm JP, Marsden DE, Hacker NF. Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. *Int J Gynecol Cancer*. 2006 Mar-Apr;16(2):638-42. PMID: 16681739
75. Sun TB, Yang CC, Kuo TB. Effect of hyperbaric oxygen on cardiac neural regulation in diabetic individuals with foot complications. *Diabet Med*. 2006 Apr;23(4):360-6. PMID: 16620263
76. Escobar SJ, Slade JB Jr, Hunt TK, Cianci P. Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate. *Undersea Hyperb Med*. 2005 Nov-Dec;32(6):437-43. PMID: 16509286
77. Young MH, Engleberg NC, Mulla ZD, Aronoff DM. Therapies for necrotising fasciitis. *Expert Opin Biol Ther*. 2006 Feb;6(2):155-65. PMID: 16436041
78. Eguiluz-Ordoñez R, Sánchez CE, Venegas A, Figueroa-Granados V, Hernández-Pando R. Effects of hyperbaric oxygen on peripheral nerves. *Plast Reconstr Surg*. 2006 Aug;118(2):350-7; discussion 358-9. PMID: 16874201
79. Kantariia IT, Megreladze II, Lapiashvili NN, Kanashvili MB. Changes of immunological and cytogenetic indexes in lymphocytes of patients with bacterial endocarditis under the influence of laser therapy and a hyperbaric oxygen therapy. *Georgian Med News*. 2006 Mar;(132):44-7. PMID: 16636378
80. Eguiluz-Ordoñez R, Sánchez CE, Venegas A, Figueroa-Granados V, Hernández-Pando R. Effects of hyperbaric oxygen on peripheral nerves. *Plast Reconstr Surg*. 2006 Aug;118(2):350-7; discussion 358-9. PMID: 16874201
81. Niezgoda JA, Cabigas EB, Allen HK, Simanonok JP, Kindwall EP, Krumenauer J. Managing pyoderma gangrenosum: a synergistic approach combining surgical debridement, vacuum-assisted closure, and hyperbaric oxygen therapy. *Plast Reconstr Surg*. 2006 Feb;117(2):24e-28e. PMID: 16462310
82. Markus YM, Bell MJ, Evans AW. Ischemic scleroderma wounds successfully treated with hyperbaric oxygen therapy. *J Rheumatol*. 2006 Aug;33(8):1694-6. PMID: 16881126
83. Jones K, Evans AW, Bristow RG, Levin W. Treatment of radiation proctitis with hyperbaric oxygen. *Radiother Oncol*. 2006 Jan;78(1):91-4. PMID: 16337705
84. Kutlay M, Colak A, Yildiz S, Demircan N, Akin ON. Stereotactic aspiration and antibiotic treatment combined with hyperbaric oxygen therapy in the management of bacterial brain abscesses. *Neurosurgery*. 2005 Dec;57(6):1140-6; discussion 1140-6. PMID: 16331162
85. Bennett M, Kertesz T, Yeung P. Hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss and tinnitus: a systematic review of randomized controlled trials. *J Laryngol Otol*. 2005 Oct;119(10):791-8. PMID: 16259656
86. Ozdogan M, Ersoy E, Dundar K, Albayrak L, Devay S, Gundogdu H. Beneficial effect of hyperbaric oxygenation on liver regeneration in cirrhosis. *J Surg Res*. 2005 Dec;129(2):260-4. PMID: 16140330
87. Phillips JS, Jones SE. Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa. *Cochrane Database Syst Rev*. 2005 Apr 18;(2):CD004617. PMID: 15846724
88. Teas J, Cunningham JE, Cone L, Jansen K, Raghavan SK, Nitcheva DK, Xie D, Butler WM. Can hyperbaric oxygen therapy reduce breast cancer treatment-related lymphedema? A pilot study. *J Womens Health (Larchmt)*. 2004 Nov;13(9):1008-18. PMID: 15665658
89. Korpinar S, Cimsit M, Cimsit B, Bugra D, Buyukbabani N. Adjunctive hyperbaric oxygen therapy in radiation-induced non-healing wound. *J Dermatol*. 2006 Jul;33(7):496-7. PMID: 16848825
90. Mindrup SR, Kealey GP, Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. *J Urol*. 2005 Jun;173(6):1975-7. PMID: 15879795